High materiality8/10
H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)
Why it may matterVerify against the original reporting
Buy reiteration supports continued upside potential.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
H.C. Wainwright reiterates Buy on ENTA; target raised to $20. The current price is about $13.37, implying roughly 49% upside if the target is reached.
- Target raised to $20; current price ~$13.37; ~49% upside.
Key facts
- 01
Target: $20
- 02
Posted price: $13.37
- 03
Analyst firm: H.C. Wainwright
- 04
Analyst: Brandon Folkes
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.